[Watchlist](6/21 - 6/27/20) <$SINT $AZN $DMPI $CHMA $VBIV $XSPA $MARK>
[Disclaimer]: I am not a professional, I expect you to do your own research and due diligence on any investment or trade that you may perform. None of the following is financial advice in any way shape or form. Trade at your own risk.
This week's focus for me are some important conferences around Biotech.
+ The American Association of Cancer Research, or AACR is holding its anual meeting II June 22-24, this one is important and a lot of different companies are presenting here. Cancer moves the stock price.
+ American Thoracic Society or ATS has a notable clinical trials session on June 24th
Check out my Week Ahead in Biotech for further information. Keyword filter search BP newsfeed AACR or ATS or BofA or BMO etc <SETUP TIP>
<$SINT SINTX Technologies Inc(NASDAQ: SINT) (Current Price: $0.7728) (Float: 11.791M):> SINTX Technologies Inc is a commercial biomaterial company, focuses on using its silicon nitride technology platform to develop, manufacture and sell a range of medical devices. It is also engaged in developing wear- and corrosion-resistant implant components for hip and knee arthroplasty. The company markets and sells its products to surgeons and hcectly, as well as through a network of independent sales distributors. It derives its revenue primarily from the sale of spinal fusion and fixation devices and related products used in the treatment of spine disorders.
+ Over the weekend SINTX TECHNOLOGIES "ANNOUNCED SARS-COV-2 TESTING RESULTS" "The preliminary results are encouraging," said Dr. Sonny Bal, CEO of SINTX. "The antiviral data are consistent with the well-established anti-bacterial properties of SINTX's silicon nitride, and with previously reported effectiveness against several single-strand RNA viruses. Additional testing at independent, outside laboratories is in progress to corroborate the effectiveness of silicon nitride against SARS-CoV-2."
<CHART TRADE>
[Watchlist](6/21 - 6/27/20 Continued)
<$AZN AstraZeneca PLC(NYSE: AZN) (Current Price: $53.01) (Float: 2Bish):> A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The company sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
+ AstraZeneca is set to present Phase 3 ETHOS trial data for triple-combination therapy Breztri Aerosphere, formerly PT010, in patients with moderate to very severe chronic obstructive pulmonary disease. <IMPORTANT due to Phase 3, even with a large company like this, Phase 3 data can make it move one way or the other signifcantly depending on the results>
<CHART or SWING TRADE>
[Watchlist](6/21 - 6/27/20 Continued)
<$DMPI DelMar Pharmaceuticals Inc(NASDAQ: DMPI) (Current Price: $1.09) (Float: 11.31M):> DelMar Pharmaceuticals Inc is a clinical and commercial-stage drug development company, which focuses on the research and development of drugs for the treatment of cancer. The company's principal product candidate includes VAL-083, a small-molecule chemotherapeutic agent, which is in clinical trials stage for the treatment of refractory glioblastoma multiforme, a form of brain cancer. It also has a strategic collaboration with Guangxi Wuzhou Pharmaceutical for the development of VAL-083 used in treating chronic myelogenous leukemia and lung cancer. All the business activity of the firm is functioned through the region of Canada.
+ DelMar Pharmaceuticals is due to present data from separate Phase 2 trials of dianhydrogalactitol (VAL-083) in patients with newly diagnosed MGMT-unmethylated glioblastoma as well as in patients with MGMT-unmethylated, bevacizumab-naïve glioblastoma in the recurrent or adjuvant setting.
I tried to find more information on when they will be making their presentations but wasn't able to find anything concrete. The AACR conference is the 22nd - 24th, I could expect a runup possibly into the news with appropriate price action afterwards. Keep in mind it is two separate Phase 2 results so it is also possible for one to be good and one to be bad causing weird price action.
<CHART TRADE>
[Watchlist](6/21 - 6/27/20 Continued)
<$CHMA Chiasma Inc(NASDAQ: CHMA) (Current Price: $7.04) (Float: 36.289M):> Chiasma Inc is a biopharmaceutical company that focuses on improving the lives of patients who face challenges associated with existing treatments for their rare and debilitating diseases. Its product candidate includes octreotide capsule which has completed Phase III clinical trial and it is being developed for the potential treatment of acromegaly, a rare, debilitating disease. The company offers its products in the United States and the European Union.
+ The FDA is expected to rule on <Chiasma Inc's (NASDAQ:CHMA)> NDA for Mycapssa this <Friday>, which is being evaluated as a maintenance therapy for acromegaly.
<CHART TRADE with POSSIBLE WEEKEND HOLD>
[Watchlist](6/21 - 6/27/20 Continued)
<$VBIV VBI Vaccines Inc(NASDAQ: VBIV) (Current Price: $2.89) (Float: 170.113M):> VBI Vaccines Inc is a US-based commercial-stage, the biopharmaceutical company which is engaged in developing next-generation vaccines to address unmet needs in infectious disease and immuno-oncology. The company manufactures Sci-B-Vac product which is a hepatitis B (HBV) vaccine for adults, children, and newborns. Its products include Virus-Like Particle which is vaccine platform which allows for the design of enveloped virus-like particle vaccines that closely mimic the target viruses. The company operates through the single segment being Developing vaccines to address unmet needs in infectious disease and immuno-oncology
+ <VBI Vaccines Inc (NASDAQ:VBIV)> is due to present expanded immunologic and tumor response data from the ongoing Phase 1/2a study of VBI-1901, its cancer vaccine immunotherapeutic candidate, in recurrent glioblastoma patients. <(Monday)>
<$VBIV had a great, albeit choppy, runup into the close Friday in anticipation for this presentation at AACR, I would expect it to continue to run into the news release with appropriate price action afterwards depending on the results.>
<CHART TRADE>
[Watchlist](6/21 - 6/27/20 Continued)
<$MARK Remark Holdings Inc (NASDAQ: MARK) (Current Price: $2.43) (Float: 93.548M):> Remark Holdings Inc delivers an integrated suite of AI solutions that enable businesses and organizations to solve problems, reduce risk and deliver positive outcomes. The company's easy-to-install AI products are being rolled out in a range of applications within the retail, financial, public safety, and workplace arenas. The company also owns and operates digital media properties that deliver relevant content and e-commerce solutions. The group operates in one segment namely Technology & Data Intelligence segment which provides products and services to customers based upon the data collected and processed by its proprietary data intelligence software.
+ Remark Holdings has unconfirmed by Benzinga Q1 earnings to be released July 6th. This is the second time these earnings will have been pushed back which could cause negative price action. Earnings however for Q1 is anticipated to be extremely good for Remark so keep that in mind.
+ Telpo, a maker of smart terminals, has been working with Remark for some time now and is set to unveil some groundbreaking information on June 23rd. This could cause signifcant positive price action if it is in relation to Remark.
<CHART or SWING TRADE>
[Watchlist](6/21 - 6/27/20 Continued)
<$XSPA XpresSpa Group Inc(NASDAQ: XSPA) (Current Price: $4.88) (Float: 48.845M):> XpresSpa Group Inc is a health and wellness holding company. The company is engaged in building a preeminent pure-play health and wellness services company around its core asset XpresSpa. Geographically, it generates a majority of its revenue from the United States
+ More information regarding the JFK Trials on COVID testing for XpresSpa is anticipated to be released this week or early next week. After XSPA's most recent 40M offering at the market price of 5.25, shares have been trading lower but it did rebound a bit from its lows off the offering.
<$XSPA in my opinion the offering was good for me, as a potential swing it just lowers my entry price as I do feel XSPA currently is overvalued until further information about the trials at JFK is released. However I do expect the results of the trial to be very good and for XSPA to simply explode over the next few months>
<CHART or SwING TRADE>
nice one
Thanks, love finding examples of how to collect good DD info, this rocks!
Join now or log in to leave a comment